相关实验视频

Updated: Jan 15, 2026

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

尼兰丁的抗糖尿病和伤口愈合潜力在链毒素诱导的糖尿病模型中

Yifeng Yang¹, Lei Cao², Mengjiao Wang³

¹Department of Endocrinology, The Second Hospital of Heilongjiang Province, Harbin Heilongjiang, 150000 China.

|October 13, 2025

概括

尼兰丁在治疗小鼠糖尿病足 (DFU) 中显示出显著的潜力. 这种天然化合物有助于调节血糖,促进伤口修复,为糖尿病患者提供有前途的补充疗法.

科学领域:

药理学药理学是指药理学的学科.
糖尿病学糖尿病学
伤口治愈研究研究伤口治愈研究

背景情况:

糖尿病足 (DFU) 是糖尿病的严重并发症,通常导致下肢截肢.
迫切需要为DFU和糖尿病管理制定有效的治疗策略.

研究的目的:

在小鼠模型中研究尼兰丁的抗糖尿病和伤口愈合作用.
评估尼兰丁对患有DFU的糖尿病小鼠生物化学标志物和组织病理的影响.

主要方法:

在BALB/c小鼠中,使用链毒素诱导糖尿病.
创建了糖尿病足,并用不同剂量的尼兰丁 (25和50毫克/公斤) 或胰岛素 (10 IU/公斤) 治疗小鼠.
评估的参数包括体重,食物/水摄入量,伤口关闭率,血清葡萄糖,胰岛素,HbA1c,抗氧化剂,脂质过氧化,氧化 (NO) 和氧化水平. 还进行了组织病理学分析.

主要成果:

尼兰丁治疗 (25和50毫克/公斤) 在DFU小鼠中使体重,食物和水摄入正常化.
尼兰丁显著降低了葡萄糖和HbA1c水平,同时增加了胰岛素水平.
观察到增强的抗氧化剂和酸水平,减少了NO和脂质过氧化. 改善了复上皮质化和减少了炎症,在组织病理学上注意到了这一点.

结论:

尼兰丁在实验性DFU中表现出强大的抗糖尿病和伤口愈合特性.
尼兰丁有效调节关键的生化标志物,并促进糖尿病小鼠的组织修复.
尼兰丁可以被认为是治疗糖尿病足和相关并发症的有前途的补充治疗剂.

关键词:

糖尿病糖尿病糖尿病足部足部足部足部胰岛素是一种胰岛素.没有任何的东西.链条毒素 (Streptozotocin) 是一种毒素.伤口愈合伤口愈合

更多相关视频

Preparation of Naringenin Solution for In Vivo Application

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Rapid Determination of the Thermal Nociceptive Threshold in Diabetic Rats

Rapid Determination of the Thermal Nociceptive Threshold in Diabetic Rats

Published on: May 17, 2012

相关概念视频

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...